^
BIOMARKER:

ERBB3 G284R

i
Other names: ERBB3, HER3, LCCS2, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
Entrez ID:
Related biomarkers:
11ms
[VIRTUAL] Evaluation of somatic and germline mutations in ampullary carcinoma reveals actionable targets in multiple signaling pathways (AACR 2021)
The BRAF N581I mutation is resistant to BRAF inhibitor vemurafenib but sensitive to MEK inhibitor trametinib. The PIK3CA N1044K mutation is oncogenic but its sensitivity to PIK3CA inhibitor alpelisib is unknown... Through comprehensive genomic characterization of Chinese AC patients, we identified multiple actionable mutations in multiple signaling pathways. Our findings indicated that molecular profiling can provide clinical benefits to a significant portion of AC patients.
Tumor Mutational Burden • MSi-H Biomarker • PARP Biomarker
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • PALB2 (Partner and localizer of BRCA2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • SMAD4 (SMAD family member 4) • CHEK2 (Checkpoint kinase 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • ELF3 (E74 Like ETS Transcription Factor 3) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4)
|
TP53 mutation • KRAS mutation • MSI-H/dMMR • HER-2 amplification • BRAF mutation • PIK3CA mutation • HER-2 mutation • FGFR2 mutation • PALB2 mutation • FGFR2 amplification • U2AF1 mutation • CHEK2 mutation • ERBB3 mutation • ERBB3 G284R • HER-2 R678Q
|
Mekinist (trametinib) • Zelboraf (vemurafenib) • Piqray (alpelisib)
over1year
[VIRTUAL] U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression (AACR-II 2020)
Background: U3-1402, a novel HER3-targeting antibody-drug conjugate (ADC) composed of a fully human anti-HER3 antibody (patritumab), tetrapeptide-based linker, and topoisomerase I inhibitor payload, is currently being studied in clinical trials for patients with HER3-positive breast cancer (phase 1/2, NCT02980341) and NSCLC (phase 1, NCT03260491). U3-1402 has a potential to show antitumor activity against HER3 mutant cells with the same potency as HER3WT cells, regardless of HER2 overexpression. This finding provides insights into HER3-targeted therapy, in which an efficient payload delivery via ADC-mediated internalization could be achieved for HER3 mutations.
HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HER-2 overexpression • HER-2 mutation • ERBB3 expression • ERBB3 mutation • ERBB3 overexpression • ERBB3 G284R • ERBB3 V104M
|
patritumab deruxtecan (U3-1402) • patritumab (U3-1287)
over1year
[VIRTUAL] Genomic architecture of gallbladder cancer: Results of a first prospective study. (ASCO 2020)
Phase 2 trial of frontline Trastuzumab combined with chemotherapy is ongoing... GBC is enriched in 28% of patients with ERBB2 & ERBB3 amplifications and/or mutations. FGFR2 mutation is rare in GBC. PIK3CA aberrations are common.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
PD-L1 expression • KRAS mutation • HER-2 amplification • PIK3CA mutation • MET amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • NF1 mutation • KRAS G12A • HER-2 V777L • PIK3CA amplification • HER-2 S310F • KRAS G13 • KRAS G12 • NF2 mutation • ERBB3 mutation • HER-2 L869R • ERBB3 G284R • FGFR3 amplification
|
Herceptin (trastuzumab)